Source:http://linkedlifedata.com/resource/pubmed/id/14722678
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2004-3-22
|
| pubmed:abstractText |
In advanced head and neck cancer, an organ-sparing approach comprising radiation therapy combined with intra-arterial chemotherapy has become an important technique. However, the high incidence of residual masses after therapy remains a problem. In this study, we prospectively evaluated the use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) delayed imaging for the detection of recurrence of head and neck cancer after radio-chemotherapy, and compared the FDG-PET results with those of magnetic resonance imaging (MRI) or computed tomography (CT). Forty-three lesions from 36 patients with head and neck cancer suspected to represent recurrence after radio-chemotherapy (median interval from therapy, 4 months) were studied. PET was performed at 2 h after FDG injection, and evaluated. The results were compared to those of contrast studies with MRI or CT performed within 2 weeks of the PET study, and to histological diagnosis (in all patients suspected of having recurrence) or clinical diagnosis. The lesion-based sensitivity (visual interpretation) and negative predictive value of FDG-PET (88% and 91%, respectively) were higher than those of MRI/CT (75% and 67% respectively). The specificity, accuracy and positive predictive value of FDG-PET (78%, 81% and 70%, respectively) were significantly ( P<0.05) higher than those of MRI/CT (30%, 47% and 39% respectively). Three of six patients with false positive findings had post-therapy inflammation. Receiver operating characteristic (ROC) analysis showed that retrospective evaluation with the standardised uptake ratio yielded the best results (sensitivity 87.5%, specificity 81.5%), followed by visual interpretation and then the tumour/neck muscle ratio. An FDG-PET delayed imaging protocol yielded significantly better results for the detection of recurrence of head and neck cancer after radio-chemotherapy than MRI/CT. Because of the high negative predictive value of FDG-PET (91.3%), if PET is negative, further invasive procedures may be unnecessary.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1619-7070
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
31
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
590-5
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:14722678-Adult,
pubmed-meshheading:14722678-Aged,
pubmed-meshheading:14722678-Aged, 80 and over,
pubmed-meshheading:14722678-Antineoplastic Agents,
pubmed-meshheading:14722678-Combined Modality Therapy,
pubmed-meshheading:14722678-Drug Therapy,
pubmed-meshheading:14722678-Female,
pubmed-meshheading:14722678-Fluorodeoxyglucose F18,
pubmed-meshheading:14722678-Head and Neck Neoplasms,
pubmed-meshheading:14722678-Humans,
pubmed-meshheading:14722678-Magnetic Resonance Imaging,
pubmed-meshheading:14722678-Male,
pubmed-meshheading:14722678-Middle Aged,
pubmed-meshheading:14722678-Neoplasm Recurrence, Local,
pubmed-meshheading:14722678-Positron-Emission Tomography,
pubmed-meshheading:14722678-Radiopharmaceuticals,
pubmed-meshheading:14722678-Radiotherapy,
pubmed-meshheading:14722678-Reproducibility of Results,
pubmed-meshheading:14722678-Sensitivity and Specificity,
pubmed-meshheading:14722678-Subtraction Technique,
pubmed-meshheading:14722678-Tomography, X-Ray Computed,
pubmed-meshheading:14722678-Treatment Outcome
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT.
|
| pubmed:affiliation |
Division of Nuclear Medicine, Department of Radiology, International Medical Center of Japan, 1-21-1 Toyama, 162-8655 Shinjuku, Tokyo, Japan. kkubota@imcj.hosp.go.jp
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't,
Validation Studies
|